1. Home
  2. REF vs DBVT Comparison

REF vs DBVT Comparison

Compare REF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reformation Inc. Common Stock

REF

Reformation Inc. Common Stock

N/A

Current Price

$13.60

Market Cap

904.5M

ML Signal

N/A

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

HOLD

Current Price

$8.92

Market Cap

850.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REF
DBVT
Founded
2009
2002
Country
United States
France
Employees
N/A
90
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.5M
850.9M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
REF
DBVT
Price
$13.60
$8.92
Analyst Decision
Strong Buy
Buy
Analyst Count
9
7
Target Price
$19.25
★ $38.55
AVG Volume (30 Days)
★ 555.6K
329.7K
Earning Date
11-03-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 10.26
EPS
★ N/A
N/A
Revenue
N/A
★ $5,636,000.00
Revenue This Year
$19.39
N/A
Revenue Next Year
$16.23
$1,630.16
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 35.77
52 Week Low
$11.85
$8.90
52 Week High
$17.26
$26.19

Technical Indicators

Market Signals
Indicator
REF
DBVT
Relative Strength Index (RSI) 50.77 23.59
Support Level $12.90 N/A
Resistance Level $16.24 $14.90
Average True Range (ATR) 0.61 0.47
MACD 0.18 -0.14
Stochastic Oscillator 73.54 0.12

Price Performance

Historical Comparison
REF
DBVT

About REF Reformation Inc. Common Stock

Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: